Clinical biomarker evidence for target engagement, reduction of synaptic damage and disease modification in Alzheimer’s patients treated with CT1812

Elayta (CT1812) - Cognition Therap

https://eventpilotadmin.com/web/page.php?page=IntHtml&project=AAIC19&id=35683

Lon S Schneider, MD, MS1; Anthony O Caggiano, MD, PhD2; Michael Grundman, MD3; Steve DeKosky, MD4; Roger Morgan, MD5; Kelsie Mozzoni2; Nicholas J Izzo, PhD2; Hank Safferstein, PhD2; Susan Catalano, PhD2

Jul 20, 2019